Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Tumor antigen (TA)-targeted monoclonal antibodies (mAb), trastuzumab, cetuximab, panitumumab, and rituximab, have been among the most successful new therapies in the present generation. Clinical activity is observed as a single agent, or in combination with radiotherapy or chemotherapy, against metastatic colorectal cancer, head and neck cancer, breast cancer, and follicular lymphoma. However, the activity is seen only in a minority of patients. Thus, an intense need exists to define the mechanism of action of these immunoactive mAb. Here, we discuss some of the likely immunological events that occur in treated patients: antibody-dependent cellular cytotoxicity (ADCC), cross talk among immune cells including NK cells and dendritic cells (DCs), and generation of TA-specific T lymphocyte responses. We present evidence supporting the induction of "NK:DC cross talk," leading to priming of TA-specific cellular immunity. These observations show that mAb-mediated NK cell activation can be greatly enhanced by the action of stimulatory cytokines and surface molecules on maturing DC and that NK:DC interaction facilitates the recruitment of both NK cells and DC to the tumor site(s). The cooperative, reciprocal stimulatory activity of both NK cells and DC can modulate both the innate immune response in the local tumor microenvironment and the adaptive immune response in secondary lymphoid organs. These events likely contribute to clinical activity, as well as provide a potential biomarker of response to mAb therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“enhanced uptake of tumor material and cross-presentation by DCs, followed by priming of T cells and activation of NK cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lee et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115 · cited 1×
“Various lines of evidence indicate that rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) are used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively (Table 1), and the activities are enhanced by the combination of chemotherapy or radiotherapy [2–10].”
BackgroundPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · cited 1×
“Various lines of evidence indicate that rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) are used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively (Table 1), and the activities are enhanced by the combination of chemotherapy or radiotherapy [2–10].”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“This differential sialyation may thus modulate the immunological responses against antigens [30].”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Various lines of evidence indicate that rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) are used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively (Table 1), and the activities are enhanced by the combination of chemotherapy or radiotherapy [2–10].”
BackgroundMonoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246 · cited 1×
“enhanced to around 20% by combining radiotherapy or chemotherapy with mAb therapy [ 11 ].”
BackgroundYun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 1×
“In most cases, quantitative differences define the pathogenesis of malignancy, and a correlation between the overexpression of these molecules and worse prognosis has been reported [12].”
BackgroundLevels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113 · cited 1×
“CD20, the target receptor for rituximab, triggers antiapoptotic pathways in B cells through Bcl-2 [13, 14].”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Various lines of evidence indicate that rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) are used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively (Table 1), and the activities are enhanced by the combination of chemotherapy or radiotherapy [2–10].”
BackgroundStagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496 · cited 1×
“This study disregarded ADCC as the mechanism of action of this mAb, instead showed that trastuzumab therapy induces MyD88 signaling and primes IFN-γ-producing CD8+T cells [27].”
MethodAntibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435 · cited 1×
“The dose above 10 μg/ml shows saturation in the binding and ADCC, which indicate abundant amount of mAb in vivo in circulation [1, 20, 21].”
Background
Cited by
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 668
Self-citationDesigned Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
Concha-Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y., Chandran, U., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 304
“Moreover, JAK2 inhibition might synergize with mAbs targeting PD-1 and/or CTLA-4 by enhancing ADCC of PD-1+CTL4+ lymphoid or myeloid suppressor immune infiltrates in the tumor microenvironment as well as reducing PD-L1 expression.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Ferris, Robert L.
- Venue
- Immunologic Research
- Published
- 2011-06-30
- Volume
- 50
- Issue
- 2-3
- Pages
- 248-254
- ISSN
- 0257-277X (ISSN-L)
- 1559-0755
- PMC
- PMC3415245
- OpenAlex
- W2027536435
- Cited by
- 156
- References
- 45
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 3 · 2021: 11 · 2020: 8 · 2019: 13 · 2018: 11 · 2017: 16 · 2016: 12 · 2015: 12 · 2014: 10 · 2013: 15 · 2012: 7
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Immunologic Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p01ca109688-05)
- National Cancer Institute (R01CA110249, R01CA138188, T32CA060397, P0-1 CA109688, P50CA097190)
- National Institute of Dental and Craniofacial Research (R01DE019727)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- antibody-dependent cellular cytotoxicity, NK cell activation, dendritic cell maturation, tumor microenvironment, treatment response biomarkers, trastuzumab, cetuximab, panitumumab, rituximab
- MeSH terms
- Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antigens, Neoplasm, Antineoplastic Agents, Dendritic Cells, Humans, Immunity, Cellular, Killer Cells, Natural, Neoplasms, T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. https://app.cochat.ai/papers/10.1007/s12026-011-8231-0
- The paper
- Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011). Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunologic Research. https://doi.org/10.1007/s12026-011-8231-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.